MPAM
IGMS

Monarch Partners Asset Management’s IGM Biosciences IGMS Stock Holding History

Monarch Partners Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,884
Closed -$1.31M – 169
2020
Q2 		$1.31M Buy
+17,884
New +$1.09M 0.32% 82

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Monarch Partners Asset Management's IGMS Position: Q3 2020 in Review

Monarch Partners Asset Management sold out of IGM Biosciences (IGMS) in Q3 2020, closing a stake of 17,884 shares — an estimated $1.31M sold.

Monarch Partners Asset Management first reported a position in IGMS in Q2 2020 and held it in 1 quarter. The position peaked at $1.31M in Q2 2020. 91 funds tracked by Wall St. Rank hold IGMS as of Q3 2020.

  • Monarch Partners Asset Management reported no remaining IGM Biosciences position as of Q3 2020 after selling out during the quarter.
  • Monarch Partners Asset Management sold 17,884 IGM Biosciences shares in Q3 2020, an estimated $1.31M.
  • Monarch Partners Asset Management first reported a position in IGM Biosciences in Q2 2020 and held it in 1 quarter.
  • Monarch Partners Asset Management's IGM Biosciences position peaked at $1.31M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2020.

Based on Monarch Partners Asset Management's 13F filing for Q3 2020, filed 5 Nov 2020.